within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M09A_OtherDrugsForDisordersOfTheMusculoSkeletalSystem.M09AX08_Golodirsen;

model Golodirsen
  extends Pharmacolibrary.Drugs.ATC.M.M09AX08;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>M09AX08</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Golodirsen is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping. It is approved for use in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in male pediatric patients with DMD (aged 7–13 years) following intravenous administration.</p><h4>References</h4><ol><li><p>Frank, DE, et al., &amp; Muntoni, F (2020). Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. <i>Neurology</i> 94(21) e2270–e2282. DOI:<a href=&quot;https://doi.org/10.1212/WNL.0000000000009233&quot;>10.1212/WNL.0000000000009233</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32139505/&quot;>https://pubmed.ncbi.nlm.nih.gov/32139505</a></p></li><li><p>Goey, AKL, et al., &amp; East, L (2024). Characterization of Nonclinical Drug Metabolism and Pharmacokinetic Properties of Phosphorodiamidate Morpholino Oligonucleotides, a Novel Drug Class for Duchenne Muscular Dystrophy. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 52(12) 1396–1406. DOI:<a href=&quot;https://doi.org/10.1124/dmd.124.001819&quot;>10.1124/dmd.124.001819</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39516029/&quot;>https://pubmed.ncbi.nlm.nih.gov/39516029</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Golodirsen;
